Investor Griffiths Richard Ian
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Griffiths Richard Ian . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-06-25 13D/A SLNCF / Silence Therapeutics plc 32,912,599 34,543,302
2025-05-08 13D/A SLNCF / Silence Therapeutics plc 30,933,897 32,912,599
2025-04-24 13D/A SLNCF / Silence Therapeutics plc 29,283,897 30,933,897
2025-03-31 13D/A SLNCF / Silence Therapeutics plc 27,266,001 29,283,897
2024-12-20 13D/A SLNCF / Silence Therapeutics plc 23,709,102 27,266,001
2024-03-27 13D/A SLNCF / Silence Therapeutics plc 28,722,255 23,709,102
2023-08-14 13D/A SLNCF / Silence Therapeutics plc 27,373,392 28,722,255
2022-10-20 13D/A SLNCF / Silence Therapeutics plc 25,469,271 27,373,392
2022-07-20 13D/A SLNCF / Silence Therapeutics plc 24,281,709 25,469,271
2022-06-15 13D SLNCF / Silence Therapeutics plc 20,696,352 24,281,709
2022-02-14 13G SLNCF / Silence Therapeutics plc 20,865,848 20,696,352
2021-02-17 13G SLNCF / Silence Therapeutics plc 20,865,848